Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.04.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Brice Martin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: brm4007@med.cornell.edu. Hauptthemen laut MEDLINE: Choroid Plexus Neoplasms, Carcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Choroid plexus carcinoma (CPC) is a rare infantile brain tumor with an aggressive clinical course that often leaves children with debilitating side effects due to aggressive and toxic chemotherapies. Development of novel therapeutical strategies for this disease have been extremely limited owing to the rarity of the disease and the paucity of biologically relevant substrates. We conducted the first high-throughput screen (HTS) on a human patient-derived CPC cell line (Children Cancer Hospital Egypt, CCHE-45) and identified 427 top hits highlighting key molecular targets in CPC. Furthermore, a combination screen with a wide variety of targets revealed multiple synergistic combinations that may pave the way for novel therapeutical strategies against CPC. Based on in vitro efficiency, central nervous system (CNS) penetrance ability and feasible translational potential, two combinations using a DNA alkylating or topoisomerase inhibitors in combination with an ataxia telangiectasia mutated and rad3 (ATR) inhibitor (topotecan/elimusertib and melphalan/elimusertib respectively) were validated in vitro and in vivo. Pharmacokinetic assays established increased brain penetrance with intra-arterial (IA) delivery over intra-venous (IV) delivery and demonstrated a higher CNS penetrance for the combination melphalan/elimusertib. The mechanisms of synergistic activity for melphalan/elimusertib were assessed through transcriptome analyses and showed dysregulation of key oncogenic pathways (e.g. MYC, mammalian target of rapamycin mTOR, p53) and activation of critical biological processes (e.g. DNA repair, apoptosis, hypoxia, interferon gamma). Importantly, IA administration of melphalan combined with elimusertib led to a significant increase in survival in a CPC genetic mouse model. In conclusion, this study is, to the best of our knowledge, the first that identifies multiple promising combinatorial therapeutics for CPC and emphasizes the potential of IA delivery for the treatment of CPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: brm4007@med.cornell.edu.
- Department of Neurological Surgery, Weill Cornell Medicine, New York, NY 10065, USA.
- Division of National Toxicology, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA; Division of Preclinical Innovation, National Center for Advancing Translati…
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
- Division of National Toxicology, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA; Lymphoid Malignancies Branch, National Cancer Institute, National Instit…
Förderung
- NCI NIH HHS
- Intramural NIH HHS
Zitieren
APA
Martin, B., Garman, T., Laramee, M., Wang, A., Zhang, X., Beck, E., Wilson, K., Klumpp-Thomas, C., McKnight, C., Xu, X., Hagen, N., Holland, D., Dahmane, N., Thomas, C. J., & Souweidane, M. (2023). Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.04.016
Vancouver
Martin B, Garman T, Laramee M, Wang A, Zhang X, Beck E, et al. Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.04.016
BibTeX
@article{Martin2023,
author = {Martin, Brice and Garman, Tyler and Laramee, Madeline and Wang, Amy and Zhang, Xiaohu and Beck, Erin and Wilson, Kelli and Klumpp-Thomas, Carleen and McKnight, Crystal and Xu, Xin and Hagen, Natalie and Holland, David and Dahmane, Nadia and Thomas, Craig J and Souweidane, Mark},
title = {Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.04.016}
}
EUVIMED